Multiomics study of nonalcoholic fatty liver disease

Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD). Kari Stefansson CEO of deCODE genetics and senior author on the paper and Gardar...